TriangleNCT00476476 · REGISTRY CONDITION SEARCH
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2015-05-07
In this research study we are looking to see how vulvar cancer responds to erlotinib therapy. Two distinct patient populations are targeted: women with locally advanced measurable squamous cell carcinoma of the vulva, primary or recurrent, who are candidates for definitive treatment with surgery or chemoradiation (Cohort 1) and women with radiographically measurable distant metastatic cancer either at time of presentation or with recurrence (Cohort 2). Another goal of this study is to learn more about the proteins and genes present in vulvar cancer and how they may affect response to erlotinib. Erlotinib treats cancer by preventing cancer cells from growing and multiplying. It does this by blocking certain proteins that are on the surface of some types of cancer cells. Laboratory tests show that vulvar cancer cells have high levels of these proteins.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Histologically confirmed measurable squamous cell carcinoma of the vulvar with an assessable lesion on the vulva or measurable metastatic disease. Tumors may be primary or recurrent. Patients must have plans for surgery or definitive treatment with chemotherapy +/-radiation unless they have measurable metastatic disease. * 18 years of age or older * No concurrent chemotherapy or radiotherapy * NO previous chemotherapy or radiotherapy within the preceding 1 month * ECOG performance status of 0-1 Exclusion Criteria: * Known hypersensitivity reaction to erlotinib * Other coexisting malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma * Treatment with a non-FDA approved or investigational drug within 30 days * Persistent toxicities (grade 2 or above) from previous treatment, expect alopecia or lymphedema * Serum creatinine level greater than CTC grade 2 * Pregnancy or breast feeding * Severe or uncontrolled systemic disease * Significant clinical disorder or laboratory finding that makes it potentially unsafe for the subject to participate
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- FEMALE
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.
- intervention Names
- Drug: Erlotinib
- label
- Erlotinib
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Erlotinib
- description
- Orally every day for about 4-6 weeks
- name
- Erlotinib
- other Names
- Tarceva
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 41
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Response is defined as achieving complete or partial response.Complete response (CR) for both cohorts was defined as resolution of all identified tumor masses on the vulva or disappearance of all target and non-target lesions with no evidence of new lesions documented by two disease assessments at least 4 weeks apart. For cohort 1 pts, a partial response (PR) was defined as a 30% reduction in the product of all diameters of the vulva tumor/tumors compared to baseline measurements. For cohort 2 pts, PR defined according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was at least a 30% decrease in the sum of the longest diameter (LD) of all target measurable lesions (baseline sum LD reference).
- measure
- Response Rate
- time Frame
- Assessed prior to definitive surgery or chemoradiation therapy (cohort 1 pts) or after 2 cycles of therapy (cohort 2 pts).
Full study description
- brief Summary
- In this research study we are looking to see how vulvar cancer responds to erlotinib therapy. Two distinct patient populations are targeted: women with locally advanced measurable squamous cell carcinoma of the vulva, primary or recurrent, who are candidates for definitive treatment with surgery or chemoradiation (Cohort 1) and women with radiographically measurable distant metastatic cancer either at time of presentation or with recurrence (Cohort 2). Another goal of this study is to learn more about the proteins and genes present in vulvar cancer and how they may affect response to erlotinib. Erlotinib treats cancer by preventing cancer cells from growing and multiplying. It does this by blocking certain proteins that are on the surface of some types of cancer cells. Laboratory tests show that vulvar cancer cells have high levels of these proteins.
- detailed Description
- OBJECTIVES: Primary • To determine the clinical efficacy of erlotinib in reducing the size of vulvar squamous cell cancer and /or metastatic lesions. Secondary * To determine the safety and tolerability of oral erlotinib. * To evaluate apoptosis and assess the Ki67, phospho-EGFR, EGFR mutation and EGFR amplification status of the vulvar cancer prior to and after therapy and correlate observed changes with response to therapy. * To evaluate the impact of medical treatment on the subsequent surgery for vulvar cancer when surgery is chosen as the definitive therapy. STATISTICAL DESIGN: This study used a two-stage design to evaluate efficacy of erlotinib based on response determined prior to definitive surgery or chemoradiation (cohort 1) or after every 2 cycles of erlotinib (cohort 2). The null and alternative response rates defined as achieving partial response (PR) or better were 3.5% and 15%. If 1 or more patients enrolled in stage one (n=17 patients) achieved PR or better than accrual would proceed to stage two (n=24 patients). There was 0.55 probability of stopping the trial at stage one if the true OR rate was 3.5%. If 3 or fewer responses were observed by the end of stage two, erlotinib would be deemed ineffective. The significance level of the study design was 0.0495 with a power of 85% to rule out a poor response rate of less than 3.5%.
Source references
- references
- citation
- Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct;127(1):141-6. doi: 10.1016/j.ygyno.2012.06.028. Epub 2012 Jun 26.
- pmid
- 22750258
- type
- RESULT
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-376840e3b6b603575f6c
- requested nct id
- NCT00476476
- primary nct id
- NCT00476476
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 9c84fe83f9fcdb12f3a6bb624863442db2afcee53df61c38a03e4f013f7f76a1
- payload sha256
- dee02aa295b90b770b4a78d2640ee8b4ea3a8ed669e3a410f14ba4c1d94457e5
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-376840e3b6b603575f6c
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00476476
- occurrences
- context exact
- NCT00476476
- end
- 11
- exact text
- NCT00476476
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Vulvar Cancer
- query disease state id
- ds-vulvar-cancer
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-vulvar-cancer-000.json
- source file sha256
- 9c84fe83f9fcdb12f3a6bb624863442db2afcee53df61c38a03e4f013f7f76a1
- source json pointer
- /studies/4/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 3adc09e6cee2bc68d1f520ee6493039c2f2bb1aaa5ab6de3e603540a3b498e36
Preserved source evidence · Not medical advice